국가: 싱가포르
언어: 영어
출처: HSA (Health Sciences Authority)
Gefitinib
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
L01EB01
TABLET, FILM COATED
Gefitinib 250 mg
ORAL
Prescription Only
Teva Pharmaceutical Industries, Ltd.
ACTIVE
2023-03-02
GEFITINIB-TEVA FC TABLET 250MG PRESENTATION Light brown to brown, round standard convex tablet, debossed “250 mg” on one side of the tablet and plain on the other side. Each tablet contains 250 mg gefitinib. INDICATIONS Gefitinib is indicated for the treatment of patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have activating mutations of the EGFR TK. DOSAGE AND ADMINISTRATION Gefitinib treatment should only be initiated by a medical specialist experienced in the treatment of patients with advanced NSCLC. The recommended dose of Gefitinib is one 250 mg tablet once a day, taken with or without food. If a dose of Gefitinib is missed, it should be taken as soon as the patient remembers. If it is less than 12 hours to the next dose, the patient should not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose. Where dosing of whole tablets is not possible, such as patients who are only able to swallow liquids, tablets may be administered as a dispersion in water. The tablet should be dropped into half a glass of drinking water (non- carbonated), without crushing, and the glass stirred until the tablet has dispersed (approximately 15 minutes) and the contents subsequently drunk immediately. The glass should be rinsed with a further half glass of water and the contents drunk. The liquid can also be administered via a nasogastric tube. Gefitinib is not recommended for use in children or adolescents as safety and effectiveness in these patient populations has not been studied. No dosage adjustment is required on the basis of patient age, body weight, gender, ethnicity, mild to moderate renal impairment or in patients with moderate to severe hepatic impairment due to liver metastases (see ‘PHARMACOKINETIC PROPERTIES’ section). DOSAGE ADJUSTMENT: Patients with poorly tolerated diarrhoea or skin adverse drug reactions may be successfully managed by providing a brief (up to 14 days) therapy interruption followed by 전체 문서 읽기